Bal Pharma Limited
NSE: BALPHARMAMarket Closed • NSE
Day range
52 week range
Bal Pharma Limited closed at INR95.75 (-2.04%) on volume 0.11x its 20-day average, trading 23.15% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -68.6% QoQ
2026-09-17
DIVIDEND Announced
Dividend - Rs 1.20 Per Share
2025-09-18
DIVIDEND Announced
Dividend - Rs 1.20 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
High Cash Flow Conversion: CFO/PAT averaged 4.14x over last 3 years
Risks
Elevated Leverage Burden: Debt-to-Equity stands at 1.94x
Tight Debt Servicing: Interest coverage ratio is under 2.0x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 17 Sept 2026 | Dividend | ₹1.20 / share | — | 17 Sept 2026 |
| 18 Sept 2025 | Dividend | ₹1.20 / share | — | 18 Sept 2025 |
| — | Dividend | ₹1.20 / share | — | 17 Sept 2024 |
| — | Dividend | ₹1.00 / share | — | 18 Sept 2023 |
| — | Dividend | ₹1.00 / share | — | 13 Sept 2022 |
| — | Dividend | ₹1.00 / share | — | 16 Sept 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 17 Sept 2020 |
| — | Dividend | ₹1.00 / share | — | 17 Sept 2019 |
| — | Dividend | ₹1.00 / share | — | 14 Sept 2018 |
| — | Dividend | ₹1.00 / share | — | 14 Sept 2017 |
| — | Dividend | ₹1.00 / share | — | 15 Sept 2016 |
| — | Dividend | ₹1.00 / share | — | 15 Sept 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]
IndiaHealthcare
Is Bal Pharma Limited Shariah compliant?
Bal Pharma Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (104.64%) exceeds AAOIFI threshold (≤ 33%).
What is Bal Pharma Limited's current valuation relative to peers?
Bal Pharma Limited trades at a P/E of 21.1x compared to the sector median of 37x, and a Price-to-Book of 1.9x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 1.94x. Interest coverage is 1.2x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at -1.7% while net profit growth averaged -3.2%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.